Recommendations on heart failure devices, drugs and diagnosis

The European Society of Cardiology launched new recommendations on devices, drugs and diagnosis in heart failure the during this week’s the Heart Failure Congress 2012. Among the recommendations, based on the latest research, were that left ventricular assist devices can be used as temporary support for heart failure and also for treatment. Also, cardiac resynchronisation therapy is more beneficial to patients with left bundle branch block QRS morphology and sinus rhythm and the newly discovered transcatheter valve interventions can be used for treating aortic stenosis during surgery. New pharmacological treatments were also presented. Beta blocker should be maximized as initial treatment, and treatment should include an angiotensin converting enzyme inhibitor, a beta blocker and mineralocorticoid receptor antagonist. A newly discovered biomarker for predicting heart failure, mid-regional pro-A-type natriuretic peptide, was also presented.

0 Comments
Related Articles
Elisabeth Manville
Apr 30, 2012
New method for treating accelerated aging and heart disease
Scientists at the Agency for Science, Technology and Research’s Institute of Medical Biology in Singapore found that they could dramatically... Read More
Mending a broken heart with stem cells and microRNAs
Just like a deep wound causes a scar to form on the skin’s surface, the damage sustained during a heart... Read More
Leyla Raiani
May 9, 2012
Discovery may lead to targeted heart disease treatments
University of Guelph researchers have determined the location and molecular action of abnormal heart proteins that can cause cardiac failure,... Read More